Almac releases an enhanced third-party logistics customer billing application.
Almac has released an improved third-party logistics (3PL) customer- billing application.
In response to client demand for end-to-end support of EU product launches, from import testing, country specific packaging, QP release, online ordering, direct to pharmacy distribution, and financial services, Almac have improved their customer billing software to facilitate an invoicing process on behalf of 3PL clients.
3PL orders, received directly from hospitals, clinics, and pharmacies for niche/orphan drug products, will now be processed, dispatched, and automatically invoiced on the client’s behalf. The process will be completed by reconciliation of payments to the client’s EU account, as well as debtor follow-up.
Source: Almac
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.